Codex DNA to Report Second Quarter 2022 Financial Results on Tuesday, August 9, 2022

Rhea-AI Summary

Codex DNA (Nasdaq: DNAY) will release its second quarter 2022 financial results on August 9, 2022, post-market. A conference call is set for the same day at 1:30 p.m. Pacific Time to discuss results and corporate highlights.

Investors can access the press release and live audio webcast on the company's website. Codex DNA is known for its innovative synthetic biology solutions, including the industry-standard Gibson Assembly® method and the BioXp™ system that accelerates DNA/RNA synthesis.

Positive

• Scheduled release of second quarter 2022 financial results indicates transparency and potential healthy financial performance.
• Innovative technologies such as the BioXp™ system offer significant advantages for synthetic biology applications.

Negative

• None.

SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced that it will release its second quarter 2022 financial results on Tuesday, August 9, 2022, after the market closes. In conjunction with the release, management will host a conference call on Tuesday, August 9, 2022, at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time to discuss the financial results and recent corporate highlights.

The press release and live audio webcast can be accessed via the Investors section of Codex DNA’s website at www.codexdna.com. The conference call can be accessed by registering at the following link: https://register.vevent.com/register/BI3c5895f666544e6abb6418b1b284105e. Please log in approximately 5 to 10 minutes before the event to ensure a timely connection. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. A replay of the conference call webcast will be archived on the Codex DNA's website for at least 30 days.

About Codex DNA
Codex DNA is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity’s greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Codex DNA is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp™ system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Codex DNA is a public company based in San Diego. For more information, visit codexdna.com.

Codex DNA, the Codex DNA logo, Gibson Assembly, and BioXp are trademarks of Codex DNA Inc.

Contact:
Brent Hunter
Vice President of Finance
(815) 780-0842
finance@codexdna.com

FAQ

When will Codex DNA release its Q2 2022 financial results?

Codex DNA will release its Q2 2022 financial results on August 9, 2022, after market close.

What time is Codex DNA's conference call on August 9, 2022?

The conference call will be held at 1:30 p.m. Pacific Time on August 9, 2022.

Where can I find the webcast for Codex DNA's Q2 2022 financial results?

The webcast can be accessed via the Investors section of Codex DNA’s website.

What is Codex DNA known for?

Codex DNA specializes in automated synthetic biology systems, including the BioXp™ system for rapid DNA and RNA synthesis.